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Background. Men with abdominal aortic aneurysm (AAA) who are not hospitalised for pulmonary and cardiovascular
diseases may have higher mortality due to such disorders.
Material and methods. Previous discharge diagnoses and causes of death were collected for 4,816 men aged 64e73 years
attending mass screening for AAA. Of these, 191 (4%) had an AAA. Overall, cardiovascular- and pulmonary-disease-
specific mortality was compared for men with and without AAA stratified for earlier pulmonary or cardiovascular hospital-
isations by Cox’s proportional hazards regression while adjusting for age. Absolute risk differences after five years were
calculated by life table analysis.
Results. The median observation time was 63 months. 362 men died from cardiovascular causes other than AAA, and 144
died from pulmonary causes. The cardiovascular mortality was significantly higher in aneurysm patients without previous
related hospitalisation (HR¼ 4.35, 95% CI: 2.73e6.94, P< 0.001) with an absolute mortality difference after 5 years of
16.3% (95% CI: 10.2e22.5%). Pulmonary-cause mortality was higher among men with AAA both with and without
previous hospitalisation for pulmonary causes (HR¼ 3.05; 95% CI: 1.19e7.83, P¼ 0.020, and HR¼ 3.29; 95% CI:
1.78e6.08, P< 0.001, respectively).
Conclusions. Men with AAA who had not been hospitalised for cardiovascular diseases have more than four times higher
cardiovascular mortality. Studies of cohorts being offered relevant prophylaxis may clarify the potential benefits of general
preventive actions.
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About 1%e3% of men aged 65 or more experience
rupture of an abdominal aortic aneurysm (AAA), an
event with a mortality of 85e90%. By contrast, only
5%e7% die from AAA after an elective repair. How-
ever, AAA seldom causes symptoms before rupture.
The mortality differential coupled with the asymp-
tomatic phase before rupture is a good argument for
considering screening for AAA.1e5
Since AAA is associated with chronic obstructive
pulmonary disease (COPD) and cardiovascular dis-
ease,1 ongoing screening could provide an opportunity
to prevent morbidity and mortality from other causes
through appropriately targeted interventions. Such
interventions ought to be started during and after
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COPD. An important remaining question is whether
men with AAA not previously hospitalised with car-
diovascular disease or COPD have higher mortality
due to these disorders and may therefore benefit from
preventive actions.
To explore these issues, we investigated the associa-
tion between a history of cardiovascular or pulmonary
hospitalisation and pulmonary and cardiovascular
mortality in men with AAA.
Material and Method
Study subjects were participants in a randomised
study of AAA screening conducted in Viborg County,
Denmark. From 1994 to 1998, all male county residents
aged 64e73 years had been randomised to AAA
screening (N¼ 6,333) or to control group (N¼ 6,306).
The details of the trial have been described else-
where.4 Briefly, men randomised to screening wererved.
95Cardiovascular and Pulmonary Mortality in AAA Patients
Eur J Vasc Endovasc Surg Vol 33, January 2007invited for an abdominal aortic ultrasonographic scan
at their local hospital4 The B-mode scans were carried
out with a small portable Phillips SDR 1550 with lin-
ear 4 mHz transducer and calliper light pen. The max-
imal infrarenal aortic diameter was measured in all
attenders in which the aorta could be visualised. An
AAA was defined as a maximal diameter of 30 mm
or more. Patients with an AAA were offered annual
follow-up examinations for further expansion. Pa-
tients with AAA sized 5.0 cm or more were referred
to be evaluated for vascular surgery. No general pul-
monary and cardiovascular preventive actions were
taken. Of the 6,333 men randomised to screening,
4,852 (77%) were screened for AAA, 4816 (99%) had
visible aortas and were eligible for the present study.
For all participants, we ascertained all discharge
diagnoses of COPD and cardiovascular diseases, in-
cluding hypertension, recorded before the date of
enrolment in the National Patient Registry. This regis-
try, established in 1977, records civil registration num-
ber, dates of hospitalisation and up to 20 discharge
diagnoses. Diagnoses were coded using the Danish
version of the International Classification of Diseases
(ICD), 8th revision until the end of 1993, and 10th
revision thereafter.6 The codes were used to classify
the participants according to previous cardiovascular
manifestations and COPD (Table 1).
Leading and participating causes of death occur-
ring between the enrolment date and 31.12.1999
were obtained from the national Registry of Causes
of Death. Using the ICD-10, we classified causes of
death as cardiovascular (ICD-10 codes starting with I)
or pulmonary (ICD-10 codes starting with J).
AAA-related deaths e i.e., deaths caused by rup-
tured AAA or AAA-related surgery e were censored
Table 1. Classification of previous hospital admissions for AAA-
related diseases according to the 8th and 10th WHO classification
of diseases (ICD)
Included cardiovascular
and pulmonary diseases
Included ICD classification codes
Arterial Hypertension 40000-40499,41009,41109,41209,
41309, 41409, 43000þ 09,43100þ 09,
43200þ 09, 43309, 43409, 43509,
43600-09, 43700-09, 438.00-99, I10-I15
AMIa 41009þ 41099, I21-I23
COPDb 49100-493.99, 517.00-518.99, J40-J47
Ischemic heart disease
excl. AMI
412.00-414.99, I20-I25 (excl. AMI)
PADc 440.09, 440.20,440.28-440.99,
444.00-444.19, 444.41-445.99, I70
(excl. I70.1), I73-I74 (excl.I74.2),
Stroke el. TCId 431.00-435.99, 436.01-436.99, I61-I65
a Acute myocardial infarction.
b Chronic obstructive pulmonary disease.
c Distal peripheral occlusive vascular disease.
d Transient cerebral ischaemia.from the analyses. The hospital and autopsy records
of the AAA-related deaths were reviewed by two
vascular surgeons, who classified the certainty with
which death was caused by AAA as ‘‘certain’’, ‘‘prob-
able’’, or ‘‘unlikely’’. The surgeons were unaware of
each other’s judgements or of the subjects’ random-
isation status in the original trial. Criteria were not
formulated in advance. Deaths classified by both sur-
geons as ‘‘certain’’ or ‘‘probable’’ were considered to
be caused by AAA. Other combinations of the two
judgements (‘‘probably’’ and ‘‘unlikely’’, both ‘‘un-
likely) were classified as deaths due to other causes.
No efforts were made to obtain agreement.4,5
Among the men screened for AAA, we compared
overall mortality for those with and without AAA
detected. We used Cox’s proportional hazards regres-
sion without and with adjustment for age and previ-
ous hospitalisation for pulmonary or cardiovascular
diseases. We then examined pulmonary and cardio-
vascular mortality separately for men with and with-
out previous hospitalisation for those diseases.
Kaplan Meier plots were produced for graphical illus-
tration and used to judge whether the assumption of
proportional hazards were present.
Finally, we calculated absolute risk and absolute
risk difference for death by these causes.
SPSS 10.0 and PEPI were used as statistical
software.
The trial was approved by the local ethics commit-
tee and reported to the Danish Registry Board.
The author has no potential conflicts of interests.
In accordance with the Clinical Trial Registration
Statement from the International Committee of Medi-
cal Journal Editors, the trial is registered at clinical tri-
als with the registration number: ISRCTN65822028.
Results
Of the 4,852 men screened for AAA, 4,816 (99%) had
the aorta successfully imaged, and 191 (4%) had an
AAA. The median follow-up time was 62 months
(25 and 75 percentiles: 40 and 67 months). Seven
men died of AAA-related causes. During the observa-
tion period, 593 men died of non-AAA related causes;
325 (54%) of them died at a hospital. The primary or
participating cause of death was a cardiovascular dis-
ease among 362 (61%) men, and pulmonary disease
among 144 (24%) men.
Table 2 shows mean age at enrolment, number of
deaths and prevalence of hospitalisation for cardio-
vascular disorders and COPD. Compared with men
without AAA, nearly twice as many men with AAA
96 J. S. LindholtTable 2. Age and previous hospitalisations due to cardiovascular disease or pulmonary disease among men with and without AAA
detected by screening
Without AAA With AAA
N (25)-50-(75) percentiles N (25)-50-(75) percentiles
Age (years) 4625 (65.2) 66.5 (69.7) 191 (65.3) 67.5 (70.7)
Aortic diameter (mm) 4625 (16) 18 (19) 191 (31) 34 (41)
Previous CV No 3603 77.9% 109 68.1%
Yes 1022 22.1% 82 31.9%
Previous COPD No 4316 93.3% 175 91.6%
Yes 309 6.7% 16 8.4%
CV: cardiovascular disease.
COPD: chronic obstructive pulmonary disease.had a history of hospital admission for cardiovascular
disease (32% vs. 22%, Chi Square test: P< 0.001).
Table 3 describes overall, cardiovascular and
pulmonary-related mortality among men with and
without AAA.
It is striking that two thirds of men with AAAwho
died of pulmonary related causes had no history of
hospital-recorded COPD diagnosis, and about half
of the cardiovascular deaths in this group occurred
in men without a previous hospital record of cardio-
vascular manifestations.
Men with AAA had significantly higher overall
mortality than men without AAA (Crude hazard
ratio: 2.11; 95% CI: 1.73e2.59) e even after adjustment
for age and a history of cardiovascular or COPD
hospital admission (hazard ratio¼ 1.92; 95% CI:
1.43e2.58, P< 0.001, Table 3, Fig. 1). The absolute
risk difference was 14% (Table 4). Stratified analysis re-
vealed that cardiovascular mortality was significantly
higher in men with AAAwho had not been previously
hospitalised for a cardiovascular cause (hazard
ratio¼ 4.35, 95% CI: 2.73e6.94, P< 0.001, Table 2,
Fig. 2) with an absolute risk difference after 5 yearsEur J Vasc Endovasc Surg Vol 33, January 2007of 16.3% (95% CI: 10.2e22.5%) (Table 4, Fig. 2). Pulmo-
nary related mortality was higher in men with AAA
with and without COPD admissions for pulmonary
causes (hazard ratio¼ 3.05; 1.19e7.83, P¼ 0.020, and
hazard ratio¼ 3.29; 1.78e6.08, P< 0.001, respectively)
(Table 3, Fig. 3). The absolute risk difference was
20% among those previously submitted to hospital
due to pulmonary problems, and 6% among those
never admitted to hospital due to pulmonary problems
(Table 4).
Discussion
This study demonstrated that cardiovascular and pul-
monary caused mortality were higher in men with
AAA never admitted to hospital due to cardiovascu-
lar diseases and COPD. These findings suggest that
patients with AAA may benefit from screening for
cardiovascular and pulmonary disease and appropri-
ate treatment. The absolute risk difference in cardio-
vascular related mortality was as high as 16%, so
a substantial benefit of preventive actions could beTable 3. Mortality of men with and without AAA
Non-AAA
N¼ 4625
AAA
N¼ 191
Hazard
ratioa
95% C.I. P-value
Pulmonary deaths All pulmonary deaths 127 17 3.00c 1.80e5.02 <0.001
Without previous COPD admission 81 12 3.29c 1.78e6.08 <0.001
With previous COPD admission 46 5 3.05c 1.19e7.83 0.020
Cardiovascular deaths All cardiovascular deaths 323 39b 3.00c 2.15e4.19 <0.001
Without previous CV admission 158 20b 4.35c 2.73e6.94 <0.001
With previous CV admission 165 19b 1.50c 0.93e2.41 0.097
Deaths of any cause All deaths 544 49b 1.92c 1.43e2.58 <0.001
CV: cardiovascular disease.
COPD: chronic obstructive pulmonary disease.
All deaths are adjusted for age, previous cardiovascular disease and COPD caused hospital admissions.
Total, cardiovascular and pulmonary mortality with and without stratification for history of relevant hospitalisations based on participating
causes of death. Hazards ratios from the Cox’s regression compare men with and without AAA.
a Hazard ratios comparing men with and without AAA.
b Excluding AAA-related deaths.
c Adjusting for age and concerning pulmonary deaths adjusted for previous cardiovascular caused admissions, and concerning cardio-
vascular related deaths adjusted for previous COPD admissions.
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of course, require a randomised trial.
We have earlier reported that almost all the men
with an AAA diagnosed by screening in this trial
had signs of impaired pulmonary function,7 but we
do not have data concerning cardiovascular disease,
except that approximately 50% of them had a systolic
ankle-brachial blood pressure index below 95%.8 So it
would probably be possible to define a high-risk
group for cardiovascular or pulmonary death by
a careful clinical examination, but frequently present
latent coronary and cerebral atherosclerotic lesions
would not be discovered.9 So it may be reasonable
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(hazard ratio = 1.92; 95% CI: 1.43-2.58, P < 0.001) 
Fig. 1. Survival curves for men with and without AAA
detected by screening.to consider all men with an AAA to have a higher
risk of cardiovascular mortality, especially in the light
of the finding that cardiovascular survival of men
with an AAA and no history of cardiovascular hospi-
talisation is similar to that of men with previous car-
diovascular disease and no AAA.
There are several limitations of our study: selection
bias may have happened due to non-attenders of
screening but the attendance rate of 77%was relatively
high. Selection bias may also have occurred by those
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Cox´s regression analysis adjusting for age and previous admissions for
pulmonary disease for men without a history of CV, comparing men with
and without AAA: hazard ratio: 4.35 (95 % CI: 2.73-6.94), P < 0.001.
Fig. 2. Survival until cardiovascular death in groups classi-
fied according to presence of AAA and a history of cardio-
vascular atherosclerotic disease (CV).Table 4. Absolute risk and absolute risk difference after five years of deaths of any cause, pulmonary and cardiovascular caused deaths
according to previous hospital admissions due to cardiovascular manifestations or pulmonary disease
Cumulative proportion of deaths after 5 years Absolute risk Absolute risk difference
(95% CI)Non-AAA
N¼ 4625
AAA
N¼ 191
Deaths of any cause All deaths 12.81% 26.87% 14.06% (7.43e20.69%)
Pulmonary deaths All pulmonary deaths 3.21% 10.46% 7.25% (2.61e11.89%)
Without previous COPD admission 2.18% 7.89% 5.71% (1.59e9.83%)
With previous COPD admission 16.99% 37.04% 20.01% (12.84e27.26%)
Cardiovascular deaths All cardiovascular deaths 7.96% 23.17% 15.21% (8.90e21.51%)
Without previous CV admission 5.05% 21.39% 16.34% (10.22e22.46%)
With previous CV admission 16.99% 25.53% 8.54% (1.99e15.09%)
CV: cardiovascular disease.
COPD: chronic obstructive pulmonary disease.Eur J Vasc Endovasc Surg Vol 33, January 2007
98 J. S. Lindholtdying of other reasons.However, the proportion of pre-
vious cardiovascular hospital admissions in men with
AAAwas similar to the others (40% vs. 32%, P¼ 0.761).
Secondly, misclassification of causes of death and
causes of hospital admissions is probably likely. The
autopsy rate in Denmark is very low, which may af-
fect the validity of the cause of death assignment.
While some cardiovascular diagnoses in the National
Patient Registry (such as hypertension) are consider-
ably misclassified,10 other cardiovascular diagnoses
(such as acute myocardial infarction) were shown to
be highly valid.11 The positive predictive value of
registered COPD diagnosis is as high as 90%.12 The
magnitude of any errors is unknown in our study
population. However, misclassification rates are likely
to be similar in the two groups, and if not, it could be
expected that men with a known AAA are more likely
to have additional cardiovascular diagnoses.1
There are several general cardiovascular and pul-
monary preventive actions which could be appropri-
ate for men with an AAA, especially smoking
cessation,13 since the proportion of current smokers
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Fig. 3. Survival with pulmonary disease stratified by pres-
ence of an AAA and a pre-exisisting chronic obstructive pul-
monary disease (COPD).Eur J Vasc Endovasc Surg Vol 33, January 2007is high in AAA patients. Vaccinations against pneu-
mococcus, haemophilus influenzae, and influenza14
for pulmonary prophylaxis could be considered, and
low dose aspirin,15 cholesterol lowering treatment,16
and proper antihypertensive treatment17 for cardio-
vascular prevention.
The role of statins in conservatively treated cases of
AAA is unresolved; statins have anti-inflammatory
effects that could decrease the expansion rate of the
aneurysms, while wall concentrations of MMP9 e
known to be associated with aneurysmal progression e
are reported to be lower in statin-treated cases.18 On
the other hand, lipoprotein (a) inhibits the activation
of plasminogen, and plasminogen seems to play a cen-
tral role in the activation of the proteases involved in
the aortic matrix degradation. Thus, lowering lipopro-
tein (a) could increase the aneurysm expansion rate.19
An additional question would be whether such
actions are cost effective. The absolute cardiovascular
mortality risk difference was 16%. If the benefit of diet
instruction and 40 mg of Simvastatin is as efficient as
in the British Heart Protection Study,20 such simple ac-
tion would save approximately 3.2% of all aneurysmal
patients fromdying prematurely within five years. The
Danish five year costs for such a drug dose is 1919 DKr
(Zocolip, 98 pieces¼ 103DKr), corresponding to 59,968
Dkr per saved life (Euro 8,049 or £ 5,636). However, this
will not be the net costs because the risk of suffering
a major cardiovascular event is lowered, so that hospi-
tal expenses are prevented in addition.
Our results suggest that all patients with an AAA
may benefit from general preventive pulmonary and
cardiovascular interventions. The ultimate evidence
would be a randomised trial but whether this is ethi-
cally acceptable can be questioned due to the relatively
high mortality and the relatively safe preventive ac-
tions. Consequently, additional cohort studies of pa-
tients being offered relevant prophylaxis including
costs would be very relevant.
Conclusion
Men with AAA detected by screening who have not
been hospitalised due to a cardiovascular disease
have higher cardiovascular mortality. Consequently,
theymaybenefit fromgeneral preventive actions. Stud-
ies of cohorts being offered relevant prophylaxis may
help to clarify the potential benefits of such prevention.
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